INTRODUCTION 27
The discovery of anti-tuberculosis drugs in the 1940s followed by combination chemotherapy 28 made tuberculosis a curable disease. In the developed countries, effective treatment and 29 surveillance reduced tuberculosis dramatically with high hopes of total eradication [1, 2] . 30 However, in the 1980s, it was realized that tuberculosis had not only ceased to decline in the 31 developed countries, notably the USA, but was actually increasing, particularly in major 32 cities [2] . It was also soon realized that the disease was out of control and increasing at an 33 alarming rate across most of the poorest regions of the world especially Africa due to 34 HIV/AIDS [1, 3] . Despite aggressive international efforts, tuberculosis remains a leading 35 infectious cause of death, with an estimated 8.6 million incident cases per year. In 2012, an 36 estimated 1.3 million people died from the disease. These death rates, however, only partially 37 depict the global TB threat; more than 80% of TB patients are in the economically productive 38 age of 15 to 49 years [4] . 39 40 Interestingly, global tuberculosis control efforts have been threatened by the emergence of 41 multidrug resistant tuberculosis (MDR-TB). It is the strains of Mycobacterium tuberculosis 42 which show high level resistance to both isoniazid and rifampicin, with or without resistance 43 to other anti TB drugs [4] . Alarmingly, MDR-TB is estimated to cause 4% of new 44 tuberculosis cases in the developing world. Patients infected with MDR strains are not only 45 difficult to cure but also more likely to remain sources of infection for a longer period of time 46 than those with drug susceptible organisms. MDR-TB requires longer duration of treatment 47 (up to 2 years) to achieve cure, in comparison with 6 month treatment for drug susceptible 48 3 TB, lower cure rates and even higher default rates, not minding the expensive cost of 49 treatment [5] .
51
Remarkably, due to the increasing prevalence, MDR-TB is now subdivided into basic MDR-52 TB, with resistance only to rifampicin and isoniazid, and extensive drug resistant TB (XDR-53 TB), with a similar resistance pattern but with resistance to one or more additional first and/or 54 second line drugs. Various perturbations in the individual drug target genes are responsible 55 for the genesis of anti-TB drugs resistance. Rifampicin resistance has been shown to be 56 caused by a change in the β-subunit of DNA dependent RNA polymerase, which is encoded 57 by the rpoβ gene and more than 95% of rifampicin resistant strains are associated with 58 mutations within an 81-base pair region of the rpoβ gene, which is termed rifampicin 59 resistance determinant region [6, 7, 8] . On the contrary, resistance to isoniazid is due to 60 mutations at one of two main sites, in either the katG or inhA genes [9, 10] . It is also noted 61 that these mutations are not directly connected, and so separate mutations are required for 62 organisms to change from a drug susceptible isolate to MDR-TB. Furthermore, rifampicin 63 resistance has been considered to be a surrogate marker for checking multidrug resistance in 64 clinical isolates of M. tuberculosis since rifampicin resistance is often accompanied by 65 resistance to isoniazid [7, 8] Consenting, eligible participants were screened for presence of AFB in their sputum. Two 106 sputum samples (spot and early morning) were collected in sterile screw-cap universal 107 containers from each participant on 2 consecutive days and stained by Ziehl-Neelsen's 108 method.
109
Progressively, early morning mucoid or mucopurulent sputum specimen was collected from 110 each participant with smear positive AFB test result into a sterile screw-cap universal bottle.
111
The specimen was then stored in the refrigerator until transported to the TB reference 112 laboratory of Dr Lawrence Henshaw Memorial Hospital (DLHMH) in Calabar, Cross River 113 State. Transport was done within 72hrs of collection.
114
After appropriate sample preparation, two Lowestein Jensen (LJ) medium slants were 115 cultured for each sample. Tubes were loosely capped and incubated as such at 37 o C for one 116 week in a slanted position to ensure even distribution and absorption of inoculum. After 1 117 week, tubes were incubated upright for up to 6 weeks and the caps tightened. An in-house 118 6 strain H37RV and an uninoculated tube were used as positive and negative control 119 respectively as previously reported by [15] . isolates. Sixty-one (61) primary resistance (91%) were higher than the acquired resistance (9%). Fig 5 showed could not be made.
323
Among the socio-demographic factors assessed in this study, female gender was significantly 324 associated with drug resistance. The resistance rate for the females was higher than that for 325 the males. This agrees with a study conducted in Georgia which revealed that women were 326 more at risk of drug resistance compared to men [27, 24] . The role of women as care givers 327 predispose them to developing drug resistance as they have longer contact at home with sick 328 relatives. Also because of cultural restrictions, women are educationally disadvantaged.
329
Women due to ignorance may not fully understand the importance of adherence to therapy. In 330 a study to access factors contributing to treatment adherence in Zambia, (39.1%) of the 331 females compared with (33.9%) of the males stopped taking their medication after 2 months.
332
Most of the male TB patients were older and more educated than the female TB patients [28] .
333
Gender as a significant demographic factor for drug resistance in this study agrees with the 334 report of [23] .
335
The significant association of smoking with drug resistance in this study has been 336 collaborated in other studies. According to [29] are no effective control of the availability of these drugs outside the National TB control 368 programme, some of these patients may have been treated with some of these first line anti-369 TB drugs unknowingly. Hence they are not frank cases of primary drug resistance.
370
Isolates in this study exhibited the highest resistance rate to Isoniazid, and the least to 371
Ethambutol.
[36] In a review of first-line anti-tuberculosis drug resistance reported that 372 Isoniazid had the highest resistance in Iran, in over 16-year while Ethambulol had the least.
373
[15] Showed that Isoniazid mono-resistance was highest among the first line anti-TB drugs 374 and similar pattern of drug resistance was also observed by [32] . Isoniazid is one of the main 375 drugs for TB treatment and over the years increasing levels of resistance to Isoniazid might 376 be due to incomplete treatment [37, 36] . The increased prevalence of strains with primary 377 resistance to Isoniazid is a very important indication to estimate the risk of development of 378 MDR TB [26]. In the same vein, a high proportion of isolates in this study exhibited 379 resistance to Rifampicin. Apprehensively, resistance to Rifampicn is the most pressing 380 concern in the TB management because it necessitates very long, expensive and relatively 381 toxic drug schedules and leads to poorer outcomes [35] . It has been shown that patients 382 infected with strains resistant to Rifampicin will experience a higher failure rate with short 383 course of 6 months chemotherapy [36] . Resistant isolates in this study exhibited distinct 384 patterns of drug resistance. Varying patterns of drug resistance was shown by these isolates 
